Clinical Trials Browser

OTHER × liposomal doxorubicin × Gynecologic × Clear all

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06292286 2025-06-11

SCENIC

Phase NA Recruiting

Ovarian Neoplasms

NCT06791460 2025-03-18

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Phase 2/3 Recruiting

Ovarian Cancer Recurrent

NCT00170573 2024-12-16

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Phase 2 Completed

77 enrolled 9 charts

Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03596281 2024-10-18

PEMBOV

Phase 1 Completed

Ovarian Neoplasms

NCT03598270 2024-08-30

ANITA

Phase 3 Completed

Ovarian Neoplasms

NCT01705158 2023-09-06

MYCA

Phase 1/2 Completed

Ovarian Neoplasms

NCT05976932 2023-08-04

Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer

Ovarian Neoplasms

NCT00326456 2023-03-27

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

Phase 3 Unknown

Ovarian Neoplasms

NCT01802749 2023-03-24

MITO16MANGO2b

Phase 3 Unknown

Ovarian Neoplasms

NCT02431559 2022-10-10

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

53 enrolled 22 charts

Ovarian Neoplasms

NCT02865811 2022-09-13

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

Phase 2 Completed

26 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01673217 2022-08-01

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03794778 2022-07-18

Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

Phase 4 Unknown

Carcinoma, Ovarian Epithelial

NCT01485874 2022-02-15

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Phase 1 Terminated

Ovarian Neoplasms

NCT01379989 2022-02-09

INOVATYON

Phase 3 Completed

Ovarian Neoplasms

NCT01035658 2021-10-28

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Phase 1/2 Terminated

22 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

Phase 3 Unknown

Ovarian Neoplasms

NCT02903004 2021-08-25

MITO23

Phase 3 Completed

Ovarian Neoplasms

NCT02822157 2021-01-29

CLIO

Phase 2 Unknown

Carcinoma, Ovarian Epithelial

NCT03480750 2020-11-10

Trientine

Phase 1/2 Completed

18 enrolled 16 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00846612 2019-09-30

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Phase 1 Completed

Ovarian Neoplasms, Recurrence

NCT01281514 2019-07-11

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03562533 2019-02-28

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian Neoplasms

NCT03367182 2019-01-11

REBECA

Ovarian Neoplasms

NCT03539328 2018-05-29

MITO27

Phase 2 Unknown

Ovarian Neoplasms

NCT00720096 2018-01-02

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Phase NA Terminated

4 enrolled 8 charts

Ovarian Neoplasms

NCT03335241 2017-11-13

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Phase 2 Unknown

Ovarian Neoplasms

NCT01637532 2016-01-26

PITCH

Phase 1/2 Completed

Ovarian Neoplasms

NCT00538603 2015-12-17

Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)

Phase NA Completed

Carcinoma, Ovarian Epithelial

NCT00758732 2015-09-28

Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Phase 2 Terminated

Neoplasms, Ovarian Neoplasms

NCT00945139 2015-07-31

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Phase 2 Completed

46 enrolled 11 charts

Ovarian Neoplasms

NCT00312650 2015-01-12

Doxil and Gemcitabine in Recurrent Ovarian Cancer

Phase 2 Terminated

Ovarian Neoplasms, Recurrence

NCT01202890 2014-01-08

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Phase 1 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01388621 2013-08-20

PROVE

Phase 2 Unknown

Ovarian Neoplasms, Recurrence

NCT00861120 2012-10-26

PaLiDo

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00653328 2012-05-23

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Phase 2 Terminated

15 enrolled 10 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00237627 2012-05-18

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Phase 1/2 Completed

BreastDermatologicGynecologicLymphoidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Ovarian Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Intraocular Lymphoma

NCT00189410 2010-07-20

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Phase 2 Completed

Uterine Cervical Neoplasms